Qiagen (QGEN) said Thursday it intends to open a new facility in Esplugues de Llobregat in Spain in early 2026 and will move its QIAstat-Dx operations within the Barcelona area to the new site.
The new 8,000-square-meter facility will cover the entire value chain for the QIAstat-Dx system for syndromic testing to trace the cause of an illness in respiratory, gastrointestinal and meningitis/encephalitis, the company said.
Qiagen said the new facility will house its research & development, production, sales, marketing, quality assurance, and regulatory affairs teams.
The new site will also serve as a center of excellence for R&D in microfluidics, as well as system and assay development, the company said.
Price: 43.55, Change: -0.20, Percent Change: -0.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.